De anställda köpte enligt PM idag till teckningsoptioner i Immunicum till beräknat marknadsmässigt pris och med lösen 19.90 kr 2022 för sammanlagt ca 0.9 Mkr

Köp aktier i Immunicum - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Immunicum (IMMU) - Köp aktier | Avanza

Share price look-up; Analys; Finansiella rapporter; Finansiell kalender; Garanterad nyemission 2018; Tidigare emissioner. Garanterad nyemission 2017; News & Events. Press releases; Immunicum in the News; Events We use a range of cookies to give you the best possible browsing experience. By continuing to use this website, you agree to our use of cookies.

REAL-TIME. 12:16:39 CET. 5,93. -0,04 (-0,67%). Valuta i SEK. Idag, 5,93 - 6,29, Aktier 1, 166 167 166, Vecka, 3,85.

For complete information, please visit the company’s website.

2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed

Will IMMU stock price drop / fall? Immunicum AB historical stock charts and prices, analyst ratings, financials, and today’s real-time IMMU stock price. Company profile page for Immunicum AB including stock price, company news, press releases, executives, board members, and contact information 2021-03-26 · View today's stock price, news and analysis for Immunicum AB (IMMU). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more.

: Get the latest Immunicum stock price and detailed information including news, historical charts and realtime prices.

Om du behöver mer information eller har några övriga frågor, vänligen kontakta Erik Manting, CEO. Telefon: +4687328400. E-post: ir@immunicum.com. Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders.

Idogen (Spotlight Stock Market: IDOGEN) utvecklar tolerogena Chief Medical Officer hos Idogen AB och styrelseledamot i Immunicum AB. RhoVac är noterat på Spotlight Stock Market sedan mars 2016. Rasta Group ex-utd 0,13 3/12 Hanza stämma (extra) 3/12 Immunicum stämma 3/12 KappAhl stämma 4/12 Immunicum ex-utd 0 4/12 KappAhl Share the knowledge. Please cite of private equity investors, but both the stock market and soft duals. Immunicum and TCER are activating certain immune.
Publikt aktiebolag

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations Stock analysis for Immunicum AB (IMMUBTA1) including stock price, stock chart, company news, key statistics, fundamentals and company profile. : Get the latest Immunicum stock price and detailed information including news, historical charts and realtime prices. View today's stock price, news and analysis for Immunicum AB (IMMU). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Latest Immunicum AB (IMMU:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.

Rasta Group ex-utd 0,13 3/12 Hanza stämma (extra) 3/12 Immunicum stämma 3/12 KappAhl stämma 4/12 Immunicum ex-utd 0 4/12 KappAhl Share the knowledge.
Skapa ett minimalistiskt hem

Stock analysis for Immunicum AB (IMMU:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

2020-06-01

View GETB's share price, price target, earnings, forecast, insider trades, and news at MarketBeat. Learn everything you need to know about successful options trading with this three-part video course. Si : Get the latest Immunicum stock price and detailed information including news, historical charts and realtime prices. © 2021 Insider Inc. and finanzen.net GmbH (Imprint).

Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Erik Manting, CEO. Phone: +46 (0)8 732 8400.